Dialysis

Nephrology·MeSH: Renal Insufficiency, Chronic

16 drugs in development·13 companies·3 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
auryxia	KERYX BIOPHARMACEUTICALS INC (KERYX)
cinacalcet	DR REDDYS LABORATORIES LTD (RDY)
doxercalciferol	Amneal Pharmaceuticals, Inc. (AMRX)
EVRENZO (爱瑞卓®) / roxadustat	KYNTRA BIO INC. (KYNB)
korsuva / kapruvia	Tvardi Therapeutics, Inc. (TVRD)
rayaldee	REPLIGEN CORP (RGEN)
sevelamer carbonate	Impax Laboratories, LLC (IPXL)
sevelamer carbonate	DR REDDYS LABORATORIES LTD (RDY)
sodium phenyl	MAIA Biotechnology, Inc. (MAIA)
Vafseo	Akebia Therapeutics, Inc. (AKBA)
XPHOZAH	ARDELYX, INC. (ARDX)

Phase 3(3)

Drug	Company
atev	Humacyte Inc. (HUMA)
Auryxia	Akebia Therapeutics, Inc. (AKBA)
ferric	KERYX BIOPHARMACEUTICALS INC (KERYX)

BLA Filed(1)

Drug	Company
oxylanthanum carbonate	Unicycive Therapeutics, Inc. (UNCY)

Phase 4(1)

Drug	Company
CHM intervention group	Valneva SE (VALN)

BioSniper tracks 16 drugs in development for Dialysis across 13 companies.

There are 3 clinical trials targeting Dialysis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.